MDIC Adds New Board Chair and Three Members

The Medical Device Innovation Consortium (MDIC) announced that Dr. Jijo James, chief medical officer, Medical Devices and Global External Innovation at Johnson & Johnson, has begun his role as chair of the MDIC Board of Directors. Additionally, MDIC has added three new members to its Board of Directors: Kevin Sayer, Chairman, president and CEO of Dexcom; Randall L. Rutta, CEO of the National Health Council (NHC); and Jim Hollingshead, president of ResMed’s Sleep and Respiratory Care business.
 
MDIC’s Board of Directors comprises representatives from the medical device industry, government, and patient advocacy groups who work together to advance the mission of the consortium. MDIC President and CEO, Pamela Goldberg is “excited to add their expertise to our board to help in guiding our future.”
 
James has served on the MDIC Board of Directors since 2017 and has been a member of the MDIC Executive Committee since 2018. He also previously chaired MDIC’s Clinical Science and Medical Officer group, a convening of senior scientific and medical executives from medical device and diagnostics companies, government, and non-profit organizations, that provides advice to MDIC’s board on issues regarding clinical and regulatory science and patient safety to maximize clinical and medical value. The first physician to chair the MDIC board, James began his medical career working as a primary care physician in both urban and rural community settings prior to his decades of service to patients and consumers through the health care industry.
 
“Collaboration and patient-centered innovation can help pave the way to a healthier future for everyone, everywhere. I’m honored to help lead MDIC and learn from its members as the organization continues to leverage its unique position to transform healthcare into people- and patient-focused care. It is my goal as chair of the Board of Directors of MDIC to continue to enable collaborative efforts between industry leaders, regulators, and researchers to advance medical device regulatory science, safety and innovation,” said James.
 
Sayer assumed the role of CEO of Dexcom in January 2015 and became board chairman in July 2018. He has also served as president since 2011 and has been on Dexcom’s Board of Directors since November 2008. Prior to leading Dexcom, Sayer held various management positions in his prior roles.
 
Rutta is a senior healthcare executive dedicated to policy-to-practice solutions that interpret, influence, and improve federal and state health care policies to enhance public and private sector health care innovation, outcomes, and efficiency. He joined the National Health Council in February 2021 as the organization’s CEO. As CEO, Rutta leads the NHC, as it enters its second century, with the goal of affecting change across the entire health system and promote increased access to affordable, high-value, equitable, sustainable health care. Prior to joining the NHC, Rutta was president and CEO at the American Autoimmune Related Diseases Association and at Easterseals.
 
Hollingshead was appointed president of ResMed’s Sleep and Respiratory Care business in June 2020, an extension of his role as president of Sleep, which he has held since July 2017. An industry leader in digital health, he helped create and execute ResMed’s strategy to transform its business—and the sleep therapy industry—by introducing built-in communications on its sleep apnea devices, coupled with cloud-based business process automation applications that help customers grow revenues while also cutting costs.
 
Founded in 2012, the Medical Device Innovation Consortium (MDIC) focuses on advancing medical device regulatory science throughout the total product lifecycle. MDIC’s mission is to leverage its position as the only public-private partnership of its kind to transform health care into human care. Collaborating with our partners to advance science, we enable medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access.